SAMBALPUR, India — The global market for GLP-1 receptor agonists is expected to more than double by the end of the decade, as demand for obesity, diabetes, and cardiometabolic treatments accelerates, according to a new Strategic Market Research report.
The research firm estimates the market will grow from $18.4 billion in 2024 to $41.5 billion by 2030, a compound annual growth rate of 12.3%.
Buy now or order the Full Report
Once primarily prescribed for blood glucose control in patients with Type 2 diabetes, GLP-1 receptor agonists have become one of the pharmaceutical industry's fastest-growing therapeutic categories. The report notes that these drugs are increasingly used to treat obesity, reduce cardiovascular risk, address sleep-related metabolic conditions, and support long-term chronic disease management.
Strategic Market Research said that rising rates of obesity and diabetes worldwide are fueling demand for therapies that address multiple metabolic risk factors simultaneously. As a result, GLP-1 medications are being evaluated not only for their clinical effectiveness but also for their potential to reduce long-term healthcare costs associated with obesity and diabetes-related complications.
Injectable GLP-1 therapies remain the dominant segment, accounting for approximately 82% of global revenue in 2024, or $15.1 billion. Their market leadership is supported by established physician familiarity, broad adoption across diabetes and obesity treatment pathways, and the convenience of once-weekly dosing.
However, oral GLP-1 therapies are expected to be among the market’s most significant growth drivers through 2030. Valued at approximately $3.3 billion in 2024, oral formulations could help expand use among patients reluctant to use injections and support broader adoption in primary care settings.
Type 2 diabetes remains the largest indication for GLP-1 therapies, generating approximately $12.5 billion in revenue and accounting for 68% of the global market in 2024. Obesity and weight management represented an estimated $5.9 billion and are expected to be the fastest-growing indication, as healthcare providers increasingly view obesity as a chronic disease requiring long-term treatment.
North America accounted for the largest regional share of the market in 2024, representing roughly 70% of global revenue, or $12.9 billion. The United States continues to drive growth through strong uptake of branded therapies, rising obesity prevalence, and broader use among diabetes and weight-management populations.
Retail pharmacies remain the leading distribution channel, accounting for approximately $8.3 billion in sales and 45% of the market. The report also highlighted growing opportunities for online pharmacies as telehealth platforms, digital weight-management programs, and home-delivery prescription services gain traction.
Major companies competing in the GLP-1 market include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Sanofi, Zealand Pharma, Amgen, and Innovent Biologics. Strategic Market Research said that future competition will increasingly focus on oral therapies, next-generation dual and triple agonists, cardiovascular outcomes data, manufacturing capacity, and payer access.
The report concludes that GLP-1 receptor agonists are rapidly evolving from diabetes treatments into a foundational platform for obesity care, cardiometabolic disease management, and chronic disease prevention, positioning the category for sustained growth through the rest of the decade.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
